Leveraging Machine Learning and Deep Learning Techniques for Improved Pathological Staging of Prostate Cancer
It addresses the need for more precise diagnostic tools in clinical oncology to improve treatment outcomes for prostate cancer patients, but it is incremental as it uses existing methods on new data.
This study tackled the problem of inaccurate pathological staging of prostate cancer by applying machine learning and deep learning techniques to RNA sequencing data, achieving an F1-score of up to 83% with Random Forest and accuracies around 70% with deep learning models.
Prostate cancer (Pca) continues to be a leading cause of cancer-related mortality in men, and the limitations in precision of traditional diagnostic methods such as the Digital Rectal Exam (DRE), Prostate-Specific Antigen (PSA) testing, and biopsies underscore the critical importance of accurate staging detection in enhancing treatment outcomes and improving patient prognosis. This study leverages machine learning and deep learning approaches, along with feature selection and extraction methods, to enhance PCa pathological staging predictions using RNA sequencing data from The Cancer Genome Atlas (TCGA). Gene expression profiles from 486 tumors were analyzed using advanced algorithms, including Random Forest (RF), Logistic Regression (LR), Extreme Gradient Boosting (XGB), and Support Vector Machine (SVM). The performance of the study is measured with respect to the F1-score, as well as precision and recall, all of which are calculated as weighted averages. The results reveal that the highest test F1-score, approximately 83%, was achieved by the Random Forest algorithm, followed by Logistic Regression at 80%, while both Extreme Gradient Boosting (XGB) and Support Vector Machine (SVM) scored around 79%. Furthermore, deep learning models with data augmentation achieved an accuracy of 71. 23%, while PCA-based dimensionality reduction reached an accuracy of 69.86%. This research highlights the potential of AI-driven approaches in clinical oncology, paving the way for more reliable diagnostic tools that can ultimately improve patient outcomes.